Brawn Biotech
Brawn Biotech Ltd. is a publicly listed Indian pharmaceutical formulations distributor, founded in 1986 and headquartered in New Delhi, serving government health institutions, hospitals, and pharmacies in India and international markets across twelve therapeutic segments.
- Company typePublic
- Founded1986
- HeadquartersNew Delhi, India
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Brawn Biotech does
Brawn Biotech Ltd. (formerly Brawn Pharmaceuticals Ltd.) is a publicly listed Indian pharmaceutical formulations distributor headquartered in New Delhi. Founded in 1986 and listed on the Bombay Stock Exchange (BSE Code: 530207) and Delhi Stock Exchange since 1995, the company distributes a broad portfolio of pharmaceutical formulations spanning twelve therapeutic segments: Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals. It also markets select branded specialty products such as LITHIN-S (Lecithin 525mg + Silymarin 150mg soft gel capsule for liver health).
The company operates a B2B enterprise field sales model, distributing products directly to government health institutions, hospitals, and pharmacies across India and international markets where it holds product registrations. Its go-to-market relies on institutional sales relationships built over 39 years of operation and regulatory registrations that create barriers to entry in government supply channels. The promoter and promoter group hold approximately 53.6-53.7% of shares, with the remainder distributed across approximately 3,966 public shareholders as of September 2025.
Brawn Biotech employs between 1,001 and 5,000 people and has total paid-up capital of 30,00,300 equity shares of Rs. 10 each. Its revenue model centers on one-time sales of pharmaceutical formulations across therapeutic categories, with pricing details not publicly disclosed. The company has no disclosed AI capabilities, no recent acquisitions or partnerships, and shows limited recent strategic activity beyond governance housekeeping (director regularization in 2024, SEBI compliance updates).
Brawn Biotech firmographics
Firmographics- Name
- Brawn Biotech
- Legal name
- Brawn Biotech Ltd.
- Website
- https://brawnbiotech.com
- Company type
- Public
- Founded year
- 1986
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Brawn Biotech Ltd. is a publicly listed Indian pharmaceutical formulations distributor, founded in 1986 and headquartered in New Delhi, serving government health institutions, hospitals, and pharmacies in India and international markets across twelve therapeutic segments.
- Ownership category
- akta.pro rank
Brawn Biotech industry classification
Industry- Product category
- Pharmaceutical Formulations
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industries
- Herbal & Botanical Supplements (CRADAGAD), Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
Keywords
Where Brawn Biotech is headquartered
LocationHeadquarters
- HQ city
- New Delhi
- HQ country
- India
- HQ region
- Asia
Offices1 record
Markets served
Brawn Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
Revenue model
- Pharmaceutical Formulations Sales: Distribution of pharmaceutical formulations across multiple therapeutic segments including Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals in domestic and international markets.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Brawn Biotech product offering
Product offeringCore offering
Brawn Biotech Ltd. manufactures and distributes pharmaceutical formulations across twelve therapeutic segments including Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals. The company also markets branded products such as LITHIN-S (Lecithin 525mg + Silymarin 150mg Soft Gel Capsule) for liver health, supplying health institutions, pharmacies, and government departments in India and international markets.
Product overview
Brawn Biotech is a pharmaceutical distribution company that offers a broad portfolio of pharmaceutical formulations covering therapeutic segments including Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals. The company also markets specific branded products such as LITHIN-S (Lecithin + Silymarin soft gel capsule for liver health). The company operates in both domestic Indian markets and international markets.
Differentiator
Problem solved
Functional benefit
Companies that use Brawn Biotech
Customer profileSegments1 record
Ideal customer profiles1 record
Brawn Biotech technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Brawn Biotech partnerships and signals
Strategic signalScale indicators4 records
Recent moves8 records
Expansion highlights3 records
Brawn Biotech competitors and assessment
Company assessmentBroad incumbents
- Sun Pharmaceutical Industries: Largest Indian generic pharmaceutical company with the broadest therapeutic portfolio in the country; the dominant incumbent against whom mid/small-cap players like Brawn Biotech compete in domestic and international tenders.
- Lupin: Major Indian generic pharma with cardiovascular, anti-diabetic, anti-infective, and respiratory focus — directly overlapping Brawn's therapeutic portfolio; incumbent reference point for institutional tender pricing.
- Cipla: Major Indian pharma incumbent with deep presence in respiratory, anti-infective, and cardiovascular generics — categories where Brawn also competes; serves as a benchmark for scale, regulatory capability, and export footprint.
- Dr. Reddy's Laboratories: Large Indian multinational generic and specialty pharma company with significant international product registrations; representative incumbent whose export playbook mirrors Brawn's stated strategy.
Direct peers
- Ipca Laboratories: Mid-tier Indian generic pharmaceutical manufacturer with a similarly diversified portfolio spanning anti-infectives, cardiovascular, anti-diabetic, and pain management segments; comparable therapeutic breadth and institutional/government sales channels in domestic and emerging markets.
- Natco Pharma: Indian pharma company with comparable mix of domestic institutional sales and international exports, focused on generics and specialty pharma; similar mid-cap positioning and regulatory-registration-driven go-to-market.
- Alembic Pharmaceuticals: Indian generic pharma with overlapping therapeutic segments (anti-infectives, cardiology, anti-diabetic) and active institutional/government sales; similar size tier and business model as Brawn Biotech.
- Ajanta Pharma: Mid-sized Indian specialty generic manufacturer with broad therapeutic coverage and strong presence in emerging-market institutional channels; closely comparable in scale, therapeutic breadth, and B2B distribution model.
- Unichem Laboratories: Indian generic pharma company of similar scale with multi-therapeutic coverage including gastrointestinal, cardiovascular, and anti-infectives; competes directly for institutional tenders and distributor relationships in India.
Emerging players
- Windlas Biotech: Smaller Indian pharma with presence in formulations and contract manufacturing; illustrates the small/mid-cap tier in which Brawn Biotech operates and the competitive dynamics of niche Indian formulators.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Brawn Biotech social profiles
Digital presenceBrawn Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Brawn Biotech leadership team
Management profileNumber of profiles
Profiles8 records
Brawn Biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Brawn Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Brawn Biotech
What does Brawn Biotech do?
Brawn Biotech Ltd. manufactures and distributes pharmaceutical formulations across twelve therapeutic segments including Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals. The company also markets branded products such as LITHIN-S (Lecithin 525mg + Silymarin 150mg Soft Gel Capsule) for liver health, supplying health institutions, pharmacies, and government departments in India and international markets.
Is Brawn Biotech a public or private company?
Brawn Biotech is a public company. It is classified as public and is currently operating.
When was Brawn Biotech founded?
Brawn Biotech was founded in 1986. It employs 1 to 10 people.
Where is Brawn Biotech based?
Brawn Biotech is headquartered in New Delhi, India, in the Asia region.
How does Brawn Biotech make money?
One revenue line is on record: pharmaceutical Formulations Sales.
Who are Brawn Biotech's main competitors?
Broad incumbents on record are Sun Pharmaceutical Industries, Lupin, Cipla and Dr. Reddy's Laboratories. Direct peers are Ipca Laboratories, Natco Pharma, Alembic Pharmaceuticals, Ajanta Pharma and Unichem Laboratories. Windlas Biotech is listed as an emerging player.
Does Brawn Biotech have an API?
No public API is recorded for Brawn Biotech.
What industry is Brawn Biotech in?
Brawn Biotech's product category is Pharmaceutical Formulations. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of CRADAGAD, Herbal & Botanical Supplements. Its NAICS code is 325412 and its SIC code is 2834.